Steven Kanner

All filings by Steven Kanner on record concern Caribou Biosciences, Inc., in the capacity of senior executive. The record holds 14 filings, for trades running from 12 October 2021 to 21 February 2025.

Market trades split into 3 purchases (€191k) and 2 sales (€491k). Sales outweigh purchases by €300k. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The rest of the record consists of 2 share grants and 7 option exercises. So far in 2025, the count stands at no purchases and 1 sale.

The median purchase comes to €34k. On 3 out of 3 purchases, another insider of the same company was buying within the same 30 days. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase.

On 21 February 2025 came the latest disclosure, an open-market sale for €4,582 in Caribou Biosciences, Inc. The last purchase on record was published on 13 October 2021, which is 1,852 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 1 day. US insiders must file a Form 4 within two business days of a trade. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.